Possibility of preventive treatment for EBV-associated NK cell-lineage proliferative disorders

Internal Medicine

Volumn 42, Issue 3, 2003, Pages 250-254

  Ishii, Masaru ^a   Yamaguchi, Norihiko ^a   Ohshima, Shiro ^a   Ishii, Taeko ^a   Mori, Kiyoshi L ^b   Kimura, Hiroshi ^c   Morishima, Tsuneo ^c   Kawase, Ichiro ^a   Saeki, Yukihiko ^a,d  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d MINAMI OSAKA GENERAL HOSPITAL   (Japan)

Author keywords

Foscarnet; Severe hypersensitivity to mosquito bites (SHMB); Vidarabine

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CD3 ANTIGEN; CD56 ANTIGEN; CORTICOSTEROID; FOSCARNET; GANCICLOVIR; VIDARABINE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; DNA REPLICATION; DOSE RESPONSE; DRUG EFFECT; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; HYPERSENSITIVITY REACTION; INSECT BITE; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; NATURAL KILLER CELL LINEAGE GRANULAR LYMPHOCYTE PROLIFERATIVE DISORDER; PRECANCER; PROGNOSIS; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0037368636     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.250     Document Type: Article

References (19)

1. Ishihara S, Ohshima K, Tokura Y, et al. Hypersensitivity to mosquito bites conceals clonal lymphoproliferation of Epstein-Barr viral DNA-positive natural killer cells. Jpn J Cancer Res 88: 82-87, 1997.
2. Tokura Y, Ishihara S, Ohshima K, et al. Severe mosquito bite hypersensitivity, natural killer cell leukaemia, latent or chronic active Epstein-Barr virus infection and hydroa vacciniforme-like eruption. [letter] Br J Dermatol 138: 905-906, 1998.
3. Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev 4: 129-135, 1991.
4. Ohshima S, Ishii M, Asada H, et al. A possible mechanism of NK cell-lineage granular lymphocyte proliferative disorder (NK-GLPD) in a patient with chronic active Epstein-Barr virus infection (CAEBV) and severe hypersensitivity to mosquito bites (SHMB). Intern Med 41: 651-656, 2002.
5. Mori KL, Egashira M, Oshimi K. Differentiation stage of natural killer cell-lineage lymphoproliferative disorders based on phenotypic analysis. Br J Haematol 115: 225-228, 2001.
6. Saito I, Servenius B, Compton T, Fox RI. Detection of Epstein-Barr virus DNA by polymerase chain reaction in blood and tissue biopsies from patients with Sjögren's syndrome. J Exp Med 169: 2191-2198, 1989.
7. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47: 883-889, 1986.
8. Kanegane H, Yachie A, Miyawaki T, Tosato G. EBV-NK cells interactions and lymphoproliferative disorders. Leuk Lymphoma 29: 491-498, 1998.
9. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 37: 132-136, 1999.
10. Kedes DH, Ganem DH. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 99: 2082-2086, 1997.
11. Ishida Y, Yokota Y, Tauchi H, et al. Gancyclovir for chronic active Epstein-Barr virus infection. [letter] Lancet 341: 560-561, 1993.
12. Kawa-Ha K, Franco E, Doi S, et al. Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. [letter] Lancet 1: 154, 1987.
13. Elion GB. History, mechanism of action, spectrum and selectivity of nucleoside analogues. in: Antiviral Chemotherapy: New Directions for Clinical Application and Research. Mills J, Corey L, Eds. Elsevier, New York, 1986: 118-137.
14. Safrin S, Kemmerly S, Plotkin B, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 169: 193-196, 1994.
15. Whitley R, Alford C, Hess F, Buchanan R. Vidarabine: a preliminary review of its pharmacological properties and therapeutic use. Drugs 20: 267-282, 1980.
16. Oberg B. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 40: 213-285, 1989.
17. Balfour HH Jr. Acyclovir and other chemotherapy for herpes group viral infections. Annu Rev Med 35: 279-291, 1984.
18. Kimura H, Morita M, Tsuge I, et al. Vidarabine therapy for severe chronic active Epstein-Barr virus infection. J Pediatr Hematol Oncol 23: 294-299, 2001.
19. Oertel SH, Riess H. Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. Recent Results Cancer Res 159: 89-95, 2002.